Cervical Cancer clinical trials in Delaware

4 actively recruiting cervical cancer trials at 6 sites across Delaware.

Data from ClinicalTrials.gov · last refreshed 2026-07-27

Phase 3 Recruiting NIH

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT07061977

Sites in Delaware:

Beebe South Coastal Health Campus — Millville, Delaware
Helen F Graham Cancer Center — Newark, Delaware
Medical Oncology Hematology Consultants PA — Newark, Delaware
Beebe Health Campus — Rehoboth Beach, Delaware

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group

NCT ID: NCT02734537

Sites in Delaware:

Beebe Medical Center — Lewes, Delaware
Delaware Clinical and Laboratory Physicians PA — Newark, Delaware
Helen F Graham Cancer Center — Newark, Delaware
Medical Oncology Hematology Consultants PA — Newark, Delaware
Christiana Care Health System-Christiana Hospital — Newark, Delaware

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05136196

Sites in Delaware:

Helen F Graham Cancer Center — Newark, Delaware
Medical Oncology Hematology Consultants PA — Newark, Delaware

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…

Sponsor: Tizona Therapeutics, Inc

NCT ID: NCT04485013

Sites in Delaware:

Christiana Care Helen F. Graham Cancer Center — Newark, Delaware

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27